Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 45 h ago

BioAge Labs, Inc.: Cormorant Asset Management, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Cormorant Asset Management amended its Schedule 13G filing on BioAge Labs, disclosing a revised passive stake in the clinical-stage biotech. The SEC filing, accession 0001172661-26-005290, updates Cormorant's previously reported position but does not indicate a change in investment intent. The amendment matters because 13G updates can signal shifts in institutional ownership for a thinly traded name. Investors will watch for the specific share count and percentage in the filing text, and for any subsequent 13D or 13G filings from other holders.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Cormorant Asset Management, LP, BioAge Labs, Inc.